KR102648965B1 - 간세포 암종 검출 - Google Patents
간세포 암종 검출 Download PDFInfo
- Publication number
- KR102648965B1 KR102648965B1 KR1020197005873A KR20197005873A KR102648965B1 KR 102648965 B1 KR102648965 B1 KR 102648965B1 KR 1020197005873 A KR1020197005873 A KR 1020197005873A KR 20197005873 A KR20197005873 A KR 20197005873A KR 102648965 B1 KR102648965 B1 KR 102648965B1
- Authority
- KR
- South Korea
- Prior art keywords
- methylation
- delete delete
- dna
- seq
- hcc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010073071 hepatocellular carcinoma Diseases 0.000 title claims abstract description 133
- 231100000844 hepatocellular carcinoma Toxicity 0.000 title claims abstract description 133
- 238000001514 detection method Methods 0.000 title description 27
- 238000000034 method Methods 0.000 claims abstract description 149
- 238000007069 methylation reaction Methods 0.000 claims description 295
- 230000011987 methylation Effects 0.000 claims description 292
- 108020004414 DNA Proteins 0.000 claims description 244
- 150000007523 nucleic acids Chemical class 0.000 claims description 175
- 102000039446 nucleic acids Human genes 0.000 claims description 163
- 108020004707 nucleic acids Proteins 0.000 claims description 163
- 239000000523 sample Substances 0.000 claims description 143
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims description 74
- 108090000623 proteins and genes Proteins 0.000 claims description 68
- 206010028980 Neoplasm Diseases 0.000 claims description 53
- 239000003153 chemical reaction reagent Substances 0.000 claims description 49
- 102100023823 Homeobox protein EMX1 Human genes 0.000 claims description 37
- 101001048956 Homo sapiens Homeobox protein EMX1 Proteins 0.000 claims description 37
- 201000011510 cancer Diseases 0.000 claims description 34
- 238000004458 analytical method Methods 0.000 claims description 33
- 238000007855 methylation-specific PCR Methods 0.000 claims description 31
- 108091029430 CpG site Proteins 0.000 claims description 29
- 102100030309 Homeobox protein Hox-A1 Human genes 0.000 claims description 25
- 101001083156 Homo sapiens Homeobox protein Hox-A1 Proteins 0.000 claims description 25
- 102100028571 Disabled homolog 2-interacting protein Human genes 0.000 claims description 23
- 101000915396 Homo sapiens Disabled homolog 2-interacting protein Proteins 0.000 claims description 23
- 101000658628 Homo sapiens Testis-specific Y-encoded-like protein 5 Proteins 0.000 claims description 23
- 102100034914 Testis-specific Y-encoded-like protein 5 Human genes 0.000 claims description 23
- 239000013068 control sample Substances 0.000 claims description 13
- 108091026890 Coding region Proteins 0.000 claims description 11
- 230000001105 regulatory effect Effects 0.000 claims description 7
- 238000012268 genome sequencing Methods 0.000 claims description 4
- 108010076804 DNA Restriction Enzymes Proteins 0.000 claims description 3
- 238000009585 enzyme analysis Methods 0.000 claims description 3
- 239000000203 mixture Substances 0.000 abstract description 35
- 238000012216 screening Methods 0.000 abstract description 15
- 125000003729 nucleotide group Chemical group 0.000 description 109
- 239000002773 nucleotide Substances 0.000 description 95
- 239000003550 marker Substances 0.000 description 83
- 238000003556 assay Methods 0.000 description 70
- 239000013615 primer Substances 0.000 description 58
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical group NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 55
- 238000003752 polymerase chain reaction Methods 0.000 description 55
- 238000005516 engineering process Methods 0.000 description 52
- 230000003321 amplification Effects 0.000 description 51
- 238000003199 nucleic acid amplification method Methods 0.000 description 51
- 210000001519 tissue Anatomy 0.000 description 44
- 238000006243 chemical reaction Methods 0.000 description 37
- 108091034117 Oligonucleotide Proteins 0.000 description 36
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 34
- 210000002381 plasma Anatomy 0.000 description 33
- 239000000090 biomarker Substances 0.000 description 30
- 210000004027 cell Anatomy 0.000 description 29
- 230000007067 DNA methylation Effects 0.000 description 28
- 108091029523 CpG island Proteins 0.000 description 26
- 108091008146 restriction endonucleases Proteins 0.000 description 26
- 108091028043 Nucleic acid sequence Proteins 0.000 description 25
- 230000007882 cirrhosis Effects 0.000 description 25
- 208000019425 cirrhosis of liver Diseases 0.000 description 25
- 206010016654 Fibrosis Diseases 0.000 description 24
- 238000012163 sequencing technique Methods 0.000 description 24
- 229940104302 cytosine Drugs 0.000 description 22
- 230000035945 sensitivity Effects 0.000 description 22
- 239000011324 bead Substances 0.000 description 21
- 239000012472 biological sample Substances 0.000 description 21
- 210000004185 liver Anatomy 0.000 description 21
- 239000000872 buffer Substances 0.000 description 20
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 19
- 201000010099 disease Diseases 0.000 description 19
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 18
- -1 Chr12.133 Proteins 0.000 description 17
- 230000008859 change Effects 0.000 description 17
- 230000008569 process Effects 0.000 description 17
- 102000004190 Enzymes Human genes 0.000 description 16
- 108090000790 Enzymes Proteins 0.000 description 16
- 238000003745 diagnosis Methods 0.000 description 16
- 238000004393 prognosis Methods 0.000 description 16
- 238000012360 testing method Methods 0.000 description 16
- 230000000295 complement effect Effects 0.000 description 15
- 208000035475 disorder Diseases 0.000 description 15
- 101001017833 Homo sapiens Leucine-rich repeat-containing protein 4 Proteins 0.000 description 14
- 102100033304 Leucine-rich repeat-containing protein 4 Human genes 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- 239000012634 fragment Substances 0.000 description 14
- 108091033319 polynucleotide Proteins 0.000 description 14
- 102000040430 polynucleotide Human genes 0.000 description 14
- 239000002157 polynucleotide Substances 0.000 description 14
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 14
- 102100022768 D-beta-hydroxybutyrate dehydrogenase, mitochondrial Human genes 0.000 description 13
- 101000903373 Homo sapiens D-beta-hydroxybutyrate dehydrogenase, mitochondrial Proteins 0.000 description 13
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 13
- 238000009396 hybridization Methods 0.000 description 13
- 230000005291 magnetic effect Effects 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 12
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 12
- 238000010200 validation analysis Methods 0.000 description 12
- 238000003776 cleavage reaction Methods 0.000 description 11
- 230000001613 neoplastic effect Effects 0.000 description 11
- 239000006228 supernatant Substances 0.000 description 11
- 102100022734 Acyl carrier protein, mitochondrial Human genes 0.000 description 10
- 102100032528 C-type lectin domain family 11 member A Human genes 0.000 description 10
- 101000678845 Homo sapiens Acyl carrier protein, mitochondrial Proteins 0.000 description 10
- 101000942297 Homo sapiens C-type lectin domain family 11 member A Proteins 0.000 description 10
- 101000663639 Homo sapiens Kunitz-type protease inhibitor 2 Proteins 0.000 description 10
- 101000611240 Homo sapiens Low molecular weight phosphotyrosine protein phosphatase Proteins 0.000 description 10
- 102100039020 Kunitz-type protease inhibitor 2 Human genes 0.000 description 10
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 10
- 238000005259 measurement Methods 0.000 description 10
- 229920001184 polypeptide Polymers 0.000 description 10
- 102000004196 processed proteins & peptides Human genes 0.000 description 10
- 108090000765 processed proteins & peptides Proteins 0.000 description 10
- 230000007017 scission Effects 0.000 description 10
- 102100023721 Ephrin-B2 Human genes 0.000 description 9
- 101001049392 Homo sapiens Ephrin-B2 Proteins 0.000 description 9
- 238000002955 isolation Methods 0.000 description 9
- 108020004999 messenger RNA Proteins 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 238000011160 research Methods 0.000 description 9
- 239000011534 wash buffer Substances 0.000 description 9
- 102100028570 Drebrin-like protein Human genes 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 101000915399 Homo sapiens Drebrin-like protein Proteins 0.000 description 8
- 108010006785 Taq Polymerase Proteins 0.000 description 8
- 230000001419 dependent effect Effects 0.000 description 8
- 238000003753 real-time PCR Methods 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 8
- 229940035893 uracil Drugs 0.000 description 8
- 108700028369 Alleles Proteins 0.000 description 7
- 108091092195 Intron Proteins 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000002068 genetic effect Effects 0.000 description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
- 229940113082 thymine Drugs 0.000 description 7
- 101150104383 ALOX5AP gene Proteins 0.000 description 6
- 102100025514 ATP-dependent 6-phosphofructokinase, platelet type Human genes 0.000 description 6
- 108091093088 Amplicon Proteins 0.000 description 6
- 102100029112 Endothelin-converting enzyme 1 Human genes 0.000 description 6
- 101000693765 Homo sapiens ATP-dependent 6-phosphofructokinase, platelet type Proteins 0.000 description 6
- 101000841259 Homo sapiens Endothelin-converting enzyme 1 Proteins 0.000 description 6
- 101000654335 Homo sapiens Secernin-1 Proteins 0.000 description 6
- 101100236114 Mus musculus Lrrfip1 gene Proteins 0.000 description 6
- 102100031312 Secernin-1 Human genes 0.000 description 6
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 239000012298 atmosphere Substances 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 5
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 238000000137 annealing Methods 0.000 description 5
- 238000001369 bisulfite sequencing Methods 0.000 description 5
- 230000000903 blocking effect Effects 0.000 description 5
- 208000035269 cancer or benign tumor Diseases 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000002759 chromosomal effect Effects 0.000 description 5
- 230000006326 desulfonation Effects 0.000 description 5
- 238000005869 desulfonation reaction Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 229940079826 hydrogen sulfite Drugs 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 210000000496 pancreas Anatomy 0.000 description 5
- 239000002987 primer (paints) Substances 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- 108010085238 Actins Proteins 0.000 description 4
- 102000007469 Actins Human genes 0.000 description 4
- 229930024421 Adenine Natural products 0.000 description 4
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 4
- 238000011529 RT qPCR Methods 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 241000282887 Suidae Species 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 229960000643 adenine Drugs 0.000 description 4
- 230000005540 biological transmission Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000000356 contaminant Substances 0.000 description 4
- 238000004925 denaturation Methods 0.000 description 4
- 230000036425 denaturation Effects 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 239000007850 fluorescent dye Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000013315 hypercross-linked polymer Substances 0.000 description 4
- 238000007477 logistic regression Methods 0.000 description 4
- 239000012139 lysis buffer Substances 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- 208000003200 Adenoma Diseases 0.000 description 3
- 206010001233 Adenoma benign Diseases 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 108060004795 Methyltransferase Proteins 0.000 description 3
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 210000000013 bile duct Anatomy 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 239000000104 diagnostic biomarker Substances 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- WBZKQQHYRPRKNJ-UHFFFAOYSA-L disulfite Chemical compound [O-]S(=O)S([O-])(=O)=O WBZKQQHYRPRKNJ-UHFFFAOYSA-L 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 239000012149 elution buffer Substances 0.000 description 3
- 210000003238 esophagus Anatomy 0.000 description 3
- 238000001917 fluorescence detection Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- 210000005228 liver tissue Anatomy 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000007837 multiplex assay Methods 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 238000006277 sulfonation reaction Methods 0.000 description 3
- 238000000108 ultra-filtration Methods 0.000 description 3
- 238000012795 verification Methods 0.000 description 3
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 2
- JYCQQPHGFMYQCF-UHFFFAOYSA-N 4-tert-Octylphenol monoethoxylate Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCO)C=C1 JYCQQPHGFMYQCF-UHFFFAOYSA-N 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 241000972773 Aulopiformes Species 0.000 description 2
- 230000030933 DNA methylation on cytosine Effects 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 102100023227 E3 SUMO-protein ligase EGR2 Human genes 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- 102000004533 Endonucleases Human genes 0.000 description 2
- 108010067770 Endopeptidase K Proteins 0.000 description 2
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 2
- 101001049692 Homo sapiens E3 SUMO-protein ligase EGR2 Proteins 0.000 description 2
- 101000653634 Homo sapiens T-box transcription factor TBX15 Proteins 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 102000016397 Methyltransferase Human genes 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 108091028664 Ribonucleotide Proteins 0.000 description 2
- 241000282849 Ruminantia Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 102100029853 T-box transcription factor TBX15 Human genes 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 2
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- ZETCGWYACBNPIH-UHFFFAOYSA-N azane;sulfurous acid Chemical compound N.OS(O)=O ZETCGWYACBNPIH-UHFFFAOYSA-N 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000012148 binding buffer Substances 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 239000008004 cell lysis buffer Substances 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 108010041758 cleavase Proteins 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 239000005547 deoxyribonucleotide Substances 0.000 description 2
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 238000001976 enzyme digestion Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000029795 kidney development Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000007834 ligase chain reaction Methods 0.000 description 2
- 210000003750 lower gastrointestinal tract Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 238000007857 nested PCR Methods 0.000 description 2
- 238000007481 next generation sequencing Methods 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 239000013307 optical fiber Substances 0.000 description 2
- 238000005192 partition Methods 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000001855 preneoplastic effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000000092 prognostic biomarker Substances 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 238000012113 quantitative test Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000002336 ribonucleotide Substances 0.000 description 2
- 125000002652 ribonucleotide group Chemical group 0.000 description 2
- 235000019515 salmon Nutrition 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 2
- 238000013022 venting Methods 0.000 description 2
- 108700026220 vif Genes Proteins 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- 108020005065 3' Flanking Region Proteins 0.000 description 1
- 108020005029 5' Flanking Region Proteins 0.000 description 1
- VHTUHGNVVZPWGO-UHFFFAOYSA-N 7-(2-hydroxyethyl)-1,3-dimethyl-8-(pyridin-3-ylmethyl)purine-2,6-dione Chemical compound OCCN1C=2C(=O)N(C)C(=O)N(C)C=2N=C1CC1=CC=CN=C1 VHTUHGNVVZPWGO-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 241000157302 Bison bison athabascae Species 0.000 description 1
- 102100024504 Bone morphogenetic protein 3 Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101100264044 Caenorhabditis elegans cwn-2 gene Proteins 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 241001466804 Carnivora Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 230000009946 DNA mutation Effects 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 108700029231 Developmental Genes Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108090000652 Flap endonucleases Proteins 0.000 description 1
- 102000004150 Flap endonucleases Human genes 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 241000282818 Giraffidae Species 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 101000762375 Homo sapiens Bone morphogenetic protein 3 Proteins 0.000 description 1
- 101000995300 Homo sapiens Protein NDRG2 Proteins 0.000 description 1
- 101000864786 Homo sapiens Secreted frizzled-related protein 2 Proteins 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 206010054949 Metaplasia Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 108020003217 Nuclear RNA Proteins 0.000 description 1
- 102000043141 Nuclear RNA Human genes 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 241001278385 Panthera tigris altaica Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108010002747 Pfu DNA polymerase Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- ZYFVNVRFVHJEIU-UHFFFAOYSA-N PicoGreen Chemical compound CN(C)CCCN(CCCN(C)C)C1=CC(=CC2=[N+](C3=CC=CC=C3S2)C)C2=CC=CC=C2N1C1=CC=CC=C1 ZYFVNVRFVHJEIU-UHFFFAOYSA-N 0.000 description 1
- 208000037062 Polyps Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102100034436 Protein NDRG2 Human genes 0.000 description 1
- 108010066717 Q beta Replicase Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000566107 Scolopax Species 0.000 description 1
- 102100030054 Secreted frizzled-related protein 2 Human genes 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 101150019524 WNT2 gene Proteins 0.000 description 1
- 108700020986 Wnt-2 Proteins 0.000 description 1
- 102000052556 Wnt-2 Human genes 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- 238000007844 allele-specific PCR Methods 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000007845 assembly PCR Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000007806 chemical reaction intermediate Substances 0.000 description 1
- VZWXIQHBIQLMPN-UHFFFAOYSA-N chromane Chemical class C1=CC=C2CCCOC2=C1 VZWXIQHBIQLMPN-UHFFFAOYSA-N 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical class O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- CTMZLDSMFCVUNX-VMIOUTBZSA-N cytidylyl-(3'->5')-guanosine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=C(C(N=C(N)N3)=O)N=C2)O)[C@@H](CO)O1 CTMZLDSMFCVUNX-VMIOUTBZSA-N 0.000 description 1
- 230000009615 deamination Effects 0.000 description 1
- 238000006481 deamination reaction Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000003066 decision tree Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007847 digital PCR Methods 0.000 description 1
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 150000002012 dioxanes Chemical class 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000001839 endoscopy Methods 0.000 description 1
- 239000005447 environmental material Substances 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000007672 fourth generation sequencing Methods 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000007274 generation of a signal involved in cell-cell signaling Effects 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 238000007849 hot-start PCR Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007851 intersequence-specific PCR Methods 0.000 description 1
- 238000007852 inverse PCR Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 238000007854 ligation-mediated PCR Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000007403 mPCR Methods 0.000 description 1
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000011880 melting curve analysis Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000015689 metaplastic ossification Effects 0.000 description 1
- 238000007856 miniprimer PCR Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 238000007838 multiplex ligation-dependent probe amplification Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 229940124276 oligodeoxyribonucleotide Drugs 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 150000002913 oxalic acids Chemical class 0.000 description 1
- 210000004923 pancreatic tissue Anatomy 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- XEBWQGVWTUSTLN-UHFFFAOYSA-M phenylmercury acetate Chemical compound CC(=O)O[Hg]C1=CC=CC=C1 XEBWQGVWTUSTLN-UHFFFAOYSA-M 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 235000008476 powdered milk Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 239000013074 reference sample Substances 0.000 description 1
- 230000001373 regressive effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000010517 secondary reaction Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000005382 thermal cycling Methods 0.000 description 1
- 238000007862 touchdown PCR Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 239000000107 tumor biomarker Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2521/00—Reaction characterised by the enzymatic activity
- C12Q2521/30—Phosphoric diester hydrolysing, i.e. nuclease
- C12Q2521/331—Methylation site specific nuclease
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2565/00—Nucleic acid analysis characterised by mode or means of detection
- C12Q2565/60—Detection means characterised by use of a special device
- C12Q2565/627—Detection means characterised by use of a special device being a mass spectrometer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/166—Oligonucleotides used as internal standards, controls or normalisation probes
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020247008512A KR102801197B1 (ko) | 2016-09-02 | 2017-09-01 | 간세포 암종 검출 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662383165P | 2016-09-02 | 2016-09-02 | |
| US62/383,165 | 2016-09-02 | ||
| PCT/US2017/049915 WO2018045322A1 (en) | 2016-09-02 | 2017-09-01 | Detecting hepatocellular carcinoma |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247008512A Division KR102801197B1 (ko) | 2016-09-02 | 2017-09-01 | 간세포 암종 검출 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20190045188A KR20190045188A (ko) | 2019-05-02 |
| KR102648965B1 true KR102648965B1 (ko) | 2024-03-18 |
Family
ID=61282051
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020197005873A Active KR102648965B1 (ko) | 2016-09-02 | 2017-09-01 | 간세포 암종 검출 |
| KR1020247008512A Active KR102801197B1 (ko) | 2016-09-02 | 2017-09-01 | 간세포 암종 검출 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247008512A Active KR102801197B1 (ko) | 2016-09-02 | 2017-09-01 | 간세포 암종 검출 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20180066320A1 (enExample) |
| EP (2) | EP4293128A3 (enExample) |
| JP (2) | JP7293109B2 (enExample) |
| KR (2) | KR102648965B1 (enExample) |
| CN (2) | CN116064795A (enExample) |
| AU (2) | AU2017318700B2 (enExample) |
| CA (1) | CA3034903A1 (enExample) |
| ES (1) | ES2956257T3 (enExample) |
| WO (1) | WO2018045322A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2522542T3 (es) | 2008-02-15 | 2014-11-17 | Mayo Foundation For Medical Education And Research | Detección de neoplasia a partir de una muestra de heces |
| US8361720B2 (en) | 2010-11-15 | 2013-01-29 | Exact Sciences Corporation | Real time cleavage assay |
| WO2015153284A1 (en) | 2014-03-31 | 2015-10-08 | Mayo Foundation For Medical Education And Research | Detecting colorectal neoplasm |
| US10184154B2 (en) | 2014-09-26 | 2019-01-22 | Mayo Foundation For Medical Education And Research | Detecting cholangiocarcinoma |
| CN107532124B (zh) | 2015-03-27 | 2022-08-09 | 精密科学公司 | 检测食管疾病 |
| KR20250171455A (ko) | 2017-01-27 | 2025-12-08 | 이그젝트 싸이언스 디블롭먼트 컴패니, 엘엘씨 | 메틸화된 dna 분석에 의한 결장 신조직형성의 검출 |
| CA3084584A1 (en) | 2017-11-30 | 2019-06-06 | Mayo Foundation For Medical Education And Research | Detecting breast cancer |
| US10648025B2 (en) | 2017-12-13 | 2020-05-12 | Exact Sciences Development Company, Llc | Multiplex amplification detection assay II |
| JP7680365B2 (ja) * | 2019-04-03 | 2025-05-20 | マヨ ファウンデーション フォア メディカル エデュケーション アンド リサーチ | 血漿中の膵管腺癌の検出 |
| WO2020214798A1 (en) * | 2019-04-17 | 2020-10-22 | The Brigham And Women's Hospital, Inc. | Epigenetic signatures of alzheimer's disease |
| KR102155044B1 (ko) * | 2019-10-08 | 2020-09-11 | 주식회사 레피다인 | 생물학적 시료의 간암 조직 기원 여부를 판별하는 방법 |
| KR102103885B1 (ko) * | 2019-10-08 | 2020-04-24 | 주식회사 레피다인 | 생물학적 시료의 간 조직 유래 여부를 판별하는 방법 |
| WO2021075797A2 (ko) * | 2019-10-14 | 2021-04-22 | 주식회사 젠큐릭스 | 특정 유전자의 cpg 메틸화 변화를 이용한 간암 진단용 조성물 및 이의 용도 |
| CN112176419B (zh) * | 2019-10-16 | 2022-03-22 | 中国医学科学院肿瘤医院 | 一种检测ctDNA中肿瘤特异基因的变异和甲基化的方法 |
| US11702704B2 (en) | 2019-10-31 | 2023-07-18 | Mayo Foundation For Medical Education And Research | Detecting ovarian cancer |
| JP2023510572A (ja) * | 2020-01-17 | 2023-03-14 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 肝細胞がんを診断するための方法 |
| WO2022018127A1 (en) * | 2020-07-21 | 2022-01-27 | Epigenomics Ag | Methods for detecting liver cancer |
| CN112011619A (zh) * | 2020-09-17 | 2020-12-01 | 山东大学深圳研究院 | Sfrp2作为标志物在乙型肝炎病毒相关肝细胞癌早期诊断中的应用及检测试剂盒 |
| CN114634981B (zh) * | 2020-12-16 | 2024-01-26 | 广州达健生物科技有限公司 | 肝癌基因甲基化检测引物探针组合及其试剂盒与应用 |
| CN117062915A (zh) * | 2021-01-12 | 2023-11-14 | 里兰斯坦福初级大学理事会 | 用于癌症诊断和预后的甲基化生物标志的分层分析 |
| WO2022243566A1 (en) * | 2021-05-21 | 2022-11-24 | Ophiomics - Investigação E Desenvolvimento Em Biotecnologia | Dna methylation biomarkers for hepatocellular carcinoma |
| WO2023010129A2 (en) * | 2021-07-30 | 2023-02-02 | Active Genomes Expressed Diagnostics, Corp. | Methods and compositions for treating liver cancer and liver disease |
| US20240401147A1 (en) * | 2021-10-19 | 2024-12-05 | Institut National de la Santé et de la Recherche Médicale | Dna methylation signature for diagnosing hepatocellular carcinoma |
| CN113897434A (zh) * | 2021-11-02 | 2022-01-07 | 北京艾克伦医疗科技有限公司 | 鉴定肝癌状态的方法和试剂盒 |
| CN113862370B (zh) * | 2021-12-02 | 2022-03-22 | 广州滴纳生物科技有限公司 | 用于筛查肝癌的引物和探针、试剂盒及其应用 |
| CN116287254B (zh) * | 2023-02-22 | 2024-04-30 | 中国人民解放军海军军医大学 | Scrn1在制备肝细胞癌分型诊断或索拉非尼疗效预测试剂盒中的应用 |
| CN116732175A (zh) * | 2023-03-09 | 2023-09-12 | 江苏鹍远生物技术有限公司 | 血浆游离dna甲基化标志物在肝脏肿瘤检测中的用途 |
| EP4678769A1 (en) * | 2023-03-09 | 2026-01-14 | Singlera Health Technologies (Shanghai) Ltd. | Use of plasma cell-free dna methylation marker in liver tumor detection |
| CN116200499B (zh) * | 2023-03-23 | 2024-01-19 | 北京和瑞精湛医学检验实验室有限公司 | 一种用于肝癌检测的基因组合与相关试剂和应用 |
| WO2024222519A1 (zh) * | 2023-04-26 | 2024-10-31 | 博尔诚(北京)科技有限公司 | 用于检测肝癌的组合物及其用途 |
| CN118685520B (zh) * | 2024-08-26 | 2024-11-26 | 湖南宏雅基因技术有限公司 | 一种肝癌基因甲基化检测的引物探针组合及试剂盒 |
| CN118834956B (zh) * | 2024-09-24 | 2024-12-06 | 上海信诺佰世医学检验有限公司 | 引物和探针组合物、试剂盒及在检测emx1、chfr基因甲基化中的应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160017430A1 (en) | 2012-05-24 | 2016-01-21 | Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) | Method for the identification of the origin of a cancer of unknown primary origin by methylation analysis |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5288609A (en) | 1984-04-27 | 1994-02-22 | Enzo Diagnostics, Inc. | Capture sandwich hybridization method and composition |
| US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5011769A (en) | 1985-12-05 | 1991-04-30 | Meiogenics U.S. Limited Partnership | Methods for detecting nucleic acid sequences |
| US5124246A (en) | 1987-10-15 | 1992-06-23 | Chiron Corporation | Nucleic acid multimers and amplified nucleic acid hybridization assays using same |
| US5359100A (en) | 1987-10-15 | 1994-10-25 | Chiron Corporation | Bifunctional blocked phosphoramidites useful in making nucleic acid mutimers |
| US5403711A (en) | 1987-11-30 | 1995-04-04 | University Of Iowa Research Foundation | Nucleic acid hybridization and amplification method for detection of specific sequences in which a complementary labeled nucleic acid probe is cleaved |
| CA1340807C (en) | 1988-02-24 | 1999-11-02 | Lawrence T. Malek | Nucleic acid amplification process |
| US5639611A (en) | 1988-12-12 | 1997-06-17 | City Of Hope | Allele specific polymerase chain reaction |
| CA2036946C (en) | 1990-04-06 | 2001-10-16 | Kenneth V. Deugau | Indexing linkers |
| US5494810A (en) | 1990-05-03 | 1996-02-27 | Cornell Research Foundation, Inc. | Thermostable ligase-mediated DNA amplifications system for the detection of genetic disease |
| US5849481A (en) | 1990-07-27 | 1998-12-15 | Chiron Corporation | Nucleic acid hybridization assays employing large comb-type branched polynucleotides |
| US5994069A (en) | 1996-01-24 | 1999-11-30 | Third Wave Technologies, Inc. | Detection of nucleic acids by multiple sequential invasive cleavages |
| US5846717A (en) | 1996-01-24 | 1998-12-08 | Third Wave Technologies, Inc. | Detection of nucleic acid sequences by invader-directed cleavage |
| US6872816B1 (en) | 1996-01-24 | 2005-03-29 | Third Wave Technologies, Inc. | Nucleic acid detection kits |
| US5338671A (en) | 1992-10-07 | 1994-08-16 | Eastman Kodak Company | DNA amplification with thermostable DNA polymerase and polymerase inhibiting antibody |
| SE501439C2 (sv) | 1993-06-22 | 1995-02-13 | Pharmacia Lkb Biotech | Sätt och anordning för analys av polynukleotidsekvenser |
| AU8102694A (en) | 1993-11-17 | 1995-06-06 | Id Biomedical Corporation | Cycling probe cleavage detection of nucleic acid sequences |
| AU1061395A (en) | 1993-11-30 | 1995-06-19 | Mcgill University | Inhibition of dna methyltransferase |
| US5851770A (en) | 1994-04-25 | 1998-12-22 | Variagenics, Inc. | Detection of mismatches by resolvase cleavage using a magnetic bead support |
| CA2188660C (en) | 1994-04-25 | 2005-01-18 | Richard G. H. Cotton | Detection of mutation by resolvase cleavage |
| WO1996020287A2 (en) | 1994-12-23 | 1996-07-04 | Behringwerke Aktiengesellschaft | Detection of nucleic acids by target-catalyzed product formation |
| US5882867A (en) | 1995-06-07 | 1999-03-16 | Dade Behring Marburg Gmbh | Detection of nucleic acids by formation of template-dependent product |
| US5773258A (en) | 1995-08-25 | 1998-06-30 | Roche Molecular Systems, Inc. | Nucleic acid amplification using a reversibly inactivated thermostable enzyme |
| US5854033A (en) | 1995-11-21 | 1998-12-29 | Yale University | Rolling circle replication reporter systems |
| US5965408A (en) | 1996-07-09 | 1999-10-12 | Diversa Corporation | Method of DNA reassembly by interrupting synthesis |
| WO1997023647A1 (en) | 1995-12-22 | 1997-07-03 | Behringwerke Aktiengesellschaft | Homogeneous amplification and detection of nucleic acids |
| US5985557A (en) | 1996-01-24 | 1999-11-16 | Third Wave Technologies, Inc. | Invasive cleavage of nucleic acids |
| JP3898228B2 (ja) | 1996-04-12 | 2007-03-28 | ザ パブリック ヘルス リサーチ インスティチュート オブ ザ シティー オブ ニューヨーク インク | 検出プローブ、キット及びアッセイ |
| US5786146A (en) | 1996-06-03 | 1998-07-28 | The Johns Hopkins University School Of Medicine | Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids |
| US6017704A (en) | 1996-06-03 | 2000-01-25 | The Johns Hopkins University School Of Medicine | Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids |
| US6096273A (en) | 1996-11-05 | 2000-08-01 | Clinical Micro Sensors | Electrodes linked via conductive oligomers to nucleic acids |
| US6251594B1 (en) | 1997-06-09 | 2001-06-26 | Usc/Norris Comprehensive Cancer Ctr. | Cancer diagnostic method based upon DNA methylation differences |
| US6013459A (en) | 1997-06-12 | 2000-01-11 | Clinical Micro Sensors, Inc. | Detection of analytes using reorganization energy |
| DE19754482A1 (de) | 1997-11-27 | 1999-07-01 | Epigenomics Gmbh | Verfahren zur Herstellung komplexer DNA-Methylierungs-Fingerabdrücke |
| US6063573A (en) | 1998-01-27 | 2000-05-16 | Clinical Micro Sensors, Inc. | Cycling probe technology using electron transfer detection |
| JP2002502614A (ja) | 1998-02-04 | 2002-01-29 | バリアジェニックス インク. | ミスマッチ検出技術 |
| US6235502B1 (en) | 1998-09-18 | 2001-05-22 | Molecular Staging Inc. | Methods for selectively isolating DNA using rolling circle amplification |
| US7700324B1 (en) | 1998-11-03 | 2010-04-20 | The Johns Hopkins University School Of Medicine | Methylated CpG island amplification (MCA) |
| EP1297182A2 (en) * | 2000-06-30 | 2003-04-02 | Epigenomics AG | Diagnosis of diseases associated with cell signalling |
| US7662594B2 (en) | 2002-09-20 | 2010-02-16 | New England Biolabs, Inc. | Helicase-dependent amplification of RNA |
| AU2004270220B2 (en) | 2003-09-05 | 2009-03-05 | The Chinese University Of Hong Kong | Method for non-invasive prenatal diagnosis |
| US20080039413A1 (en) * | 2003-10-21 | 2008-02-14 | Morris David W | Novel compositions and methods in cancer |
| PT2385143T (pt) | 2006-02-02 | 2016-10-18 | Univ Leland Stanford Junior | Rastreio genético fetal não-invasivo por análise digital |
| JP2009095262A (ja) * | 2007-10-15 | 2009-05-07 | Japan Found Cancer Res | Znフィンガータンパク質 |
| JP5651022B2 (ja) | 2008-03-15 | 2015-01-07 | ホロジック,インコーポレーテッド | 増幅反応中の核酸分子を分析するための組成物及び方法 |
| EP2233590A1 (en) * | 2009-01-28 | 2010-09-29 | AIT Austrian Institute of Technology GmbH | Methylation assay |
| WO2011109637A1 (en) * | 2010-03-03 | 2011-09-09 | Koo Foundation Sun Yat-Sen Cancer Center | Methods for classifying and treating breast cancers |
| US20110256538A1 (en) * | 2010-04-15 | 2011-10-20 | Philadelphia Health & Education Corporation D/B/A Drexel University College Of Medicine | Epigenomic dna modifications for tissue typing, early cancer detection, and disease management |
| WO2012037128A2 (en) * | 2010-09-14 | 2012-03-22 | The University Of North Carolina At Chapel Hill | Methods and kits for detecting melanoma |
| US8916344B2 (en) | 2010-11-15 | 2014-12-23 | Exact Sciences Corporation | Methylation assay |
| US8715937B2 (en) | 2010-11-15 | 2014-05-06 | Exact Sciences Corporation | Mutation detection assay |
| US8361720B2 (en) | 2010-11-15 | 2013-01-29 | Exact Sciences Corporation | Real time cleavage assay |
| US20130129668A1 (en) * | 2011-09-01 | 2013-05-23 | The Regents Of The University Of California | Diagnosis and treatment of arthritis using epigenetics |
| EP2899274A4 (en) * | 2012-09-19 | 2016-06-01 | Sysmex Corp | METHOD FOR OBTAINING INFORMATION ON HEPATOCELLULAR CARCINOMAS AND MARKERS AND KIT FOR OBTAINING INFORMATION ON HEPATOCELLULAR CARCINOMAS |
| WO2014052855A1 (en) * | 2012-09-27 | 2014-04-03 | Population Diagnostics, Inc. | Methods and compositions for screening and treating developmental disorders |
| US9506116B2 (en) * | 2013-03-14 | 2016-11-29 | Mayo Foundation For Medical Education And Research | Detecting neoplasm |
| JP6369857B2 (ja) * | 2013-05-29 | 2018-08-08 | シスメックス株式会社 | 肝細胞癌に関する情報の取得方法、ならびに肝細胞癌に関する情報を取得するためのマーカーおよびキット |
| WO2015116837A1 (en) * | 2014-01-30 | 2015-08-06 | The Regents Of The University Of California | Methylation haplotyping for non-invasive diagnosis (monod) |
| US10184154B2 (en) * | 2014-09-26 | 2019-01-22 | Mayo Foundation For Medical Education And Research | Detecting cholangiocarcinoma |
| EP3034624A1 (en) * | 2014-12-18 | 2016-06-22 | Hospital Clínic de Barcelona | Method for the prognosis of hepatocellular carcinoma |
| CN107532124B (zh) * | 2015-03-27 | 2022-08-09 | 精密科学公司 | 检测食管疾病 |
| CN104762301B (zh) * | 2015-04-24 | 2017-12-26 | 武汉大学 | 一种检测肝癌风险基因tspyl5甲基化水平的试剂盒及方法 |
| AU2017250663B2 (en) * | 2016-04-14 | 2023-06-15 | Mayo Foundation For Medical Education And Research | Detecting pancreatic high-grade dysplasia |
-
2017
- 2017-09-01 KR KR1020197005873A patent/KR102648965B1/ko active Active
- 2017-09-01 US US15/694,300 patent/US20180066320A1/en not_active Abandoned
- 2017-09-01 JP JP2019512308A patent/JP7293109B2/ja active Active
- 2017-09-01 WO PCT/US2017/049915 patent/WO2018045322A1/en not_active Ceased
- 2017-09-01 CN CN202210999151.7A patent/CN116064795A/zh active Pending
- 2017-09-01 EP EP23191397.1A patent/EP4293128A3/en active Pending
- 2017-09-01 AU AU2017318700A patent/AU2017318700B2/en active Active
- 2017-09-01 CN CN201780053034.9A patent/CN109790198B/zh active Active
- 2017-09-01 KR KR1020247008512A patent/KR102801197B1/ko active Active
- 2017-09-01 ES ES17847642T patent/ES2956257T3/es active Active
- 2017-09-01 EP EP17847642.0A patent/EP3507298B1/en active Active
- 2017-09-01 CA CA3034903A patent/CA3034903A1/en active Pending
-
2019
- 2019-10-08 US US16/596,513 patent/US20200115761A1/en active Pending
-
2022
- 2022-12-21 AU AU2022291502A patent/AU2022291502C1/en active Active
-
2023
- 2023-02-13 JP JP2023019916A patent/JP7704792B2/ja active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160017430A1 (en) | 2012-05-24 | 2016-01-21 | Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) | Method for the identification of the origin of a cancer of unknown primary origin by methylation analysis |
Non-Patent Citations (1)
| Title |
|---|
| Dig Dis Sci (2016) Vol.61, pp149-157, DOI 10.1007/s10620-015-3878-3 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109790198B (zh) | 2022-09-09 |
| US20180066320A1 (en) | 2018-03-08 |
| JP7293109B2 (ja) | 2023-06-19 |
| EP3507298A4 (en) | 2021-03-10 |
| EP4293128A3 (en) | 2024-03-20 |
| AU2022291502B2 (en) | 2025-02-20 |
| WO2018045322A1 (en) | 2018-03-08 |
| EP3507298B1 (en) | 2023-08-30 |
| AU2022291502C1 (en) | 2025-08-21 |
| ES2956257T3 (es) | 2023-12-18 |
| AU2017318700A2 (en) | 2020-01-16 |
| AU2022291502A1 (en) | 2023-02-09 |
| US20200115761A1 (en) | 2020-04-16 |
| JP2019528704A (ja) | 2019-10-17 |
| JP7704792B2 (ja) | 2025-07-08 |
| KR20190045188A (ko) | 2019-05-02 |
| CN116064795A (zh) | 2023-05-05 |
| EP3507298A1 (en) | 2019-07-10 |
| CN109790198A (zh) | 2019-05-21 |
| JP2023058645A (ja) | 2023-04-25 |
| AU2017318700B2 (en) | 2022-09-22 |
| AU2017318700A1 (en) | 2019-03-14 |
| EP4293128A2 (en) | 2023-12-20 |
| KR102801197B1 (ko) | 2025-04-29 |
| CA3034903A1 (en) | 2018-03-08 |
| KR20240038151A (ko) | 2024-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7704792B2 (ja) | 肝細胞癌の検出 | |
| US20240191308A1 (en) | Detecting gastric neoplasm | |
| US11697853B2 (en) | Detecting prostate cancer | |
| US20230028856A1 (en) | Detecting gastrointestinal neoplasms | |
| JP7277460B2 (ja) | 乳癌の検出 | |
| HK40103516A (en) | Detecting hepatocellular carcinoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20190227 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20200814 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20230620 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20231214 |
|
| A107 | Divisional application of patent | ||
| PA0104 | Divisional application for international application |
Comment text: Divisional Application for International Patent Patent event code: PA01041R01D Patent event date: 20240313 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20240314 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20240314 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration |